Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...

Stocks were rising on Wednesday following the Federal Reserve’s decision to hold interest rates steady. The central bank ...

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...